- Home
- LAB vs DBVT Comparison
LAB vs DBVT Comparison
Compare LAB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- DBVT
- Stock Information
- Founded
- LAB 1999
- DBVT 2002
- Country
- LAB United States
- DBVT France
- Employees
- LAB N/A
- DBVT N/A
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAB Industrials
- DBVT Health Care
- Exchange
- LAB Nasdaq
- DBVT Nasdaq
- Market Cap
- LAB 504.2M
- DBVT 464.0M
- IPO Year
- LAB 2011
- DBVT N/A
- Fundamental
- Price
- LAB $1.27
- DBVT $14.12
- Analyst Decision
- LAB Buy
- DBVT Buy
- Analyst Count
- LAB 2
- DBVT 4
- Target Price
- LAB $2.50
- DBVT $14.81
- AVG Volume (30 Days)
- LAB 1.6M
- DBVT 203.8K
- Earning Date
- LAB 11-04-2025
- DBVT 10-28-2025
- Dividend Yield
- LAB N/A
- DBVT N/A
- EPS Growth
- LAB N/A
- DBVT N/A
- EPS
- LAB N/A
- DBVT N/A
- Revenue
- LAB $172,271,000.00
- DBVT $3,800,000.00
- Revenue This Year
- LAB N/A
- DBVT $1,743.46
- Revenue Next Year
- LAB N/A
- DBVT $1,044.34
- P/E Ratio
- LAB N/A
- DBVT N/A
- Revenue Growth
- LAB 76.33
- DBVT N/A
- 52 Week Low
- LAB $0.92
- DBVT $2.21
- 52 Week High
- LAB $2.32
- DBVT $18.00
- Technical
- Relative Strength Index (RSI)
- LAB 45.10
- DBVT 50.21
- Support Level
- LAB $1.24
- DBVT $14.85
- Resistance Level
- LAB $1.44
- DBVT $16.95
- Average True Range (ATR)
- LAB 0.08
- DBVT 1.04
- MACD
- LAB -0.00
- DBVT -0.30
- Stochastic Oscillator
- LAB 10.32
- DBVT 0.00
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.